Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

This is a single center, open label, phase 1 lead in to determine Recommended Phase 2 Dose (RP2D), followed by a phase 2 trial to evaluate the safety and efficacy of Epo-R-CD19 CAR T with or without CD22 CAR T-cells infused into patients with B cell lymphoma. The study will have the following parts: * Screening * Pre-infusion (cell product preparation and bridging) and infusion (lymphodepletion) * Primary efficacy endpoints * Long term follow up Patients who have high risk B cell lymphoma or relapsed/refractory B cell lymphoma who fufil the trial inclusion and exclusion criteria will underg

Trial Details

NCT ID
NCT07319676
Phase
PHASE1 / PHASE2
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CART infusion
Locations (sample)
  • Singapore, Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Age 10 to 80 years at screening
  • PET-CT measurable disease by Lugano classification (Deauville score of ≥4) and
  • Tissue biopsy of any tumour site and flow cytometry study of CD19 and CD22 expression.
  • Relapsed B-cell lymphoma after one line of systemic therapy or autologous bone marrow transplant. This includes DLBCL, PMBCL, HGBCL, DLBCL arising …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →